PT-141 (bremelanotide) activates melanocortin receptors in the central nervous system to influence sexual desire — a mechanism distinct from blood-flow drugs. Here is what peer-reviewed clinical data shows, subject to medical approval by a licensed provider at TelosRX.
Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT-141 targets MC3R and MC4R receptors in the brain's hypothalamus. Branded as Vyleesi, bremelanotide received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded PT-141 is not FDA-approved and is prepared under federal compounding regulations.
Below are five benefits supported by published clinical research.
1. Central Nervous System Activation of Sexual Desire
PT-141's primary mechanism sets it apart from nearly every other agent used for sexual dysfunction. Rather than dilating blood vessels, bremelanotide binds to melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the hypothalamus — the brain region that regulates drive and arousal.
A foundational pharmacology study demonstrated that MC4R agonism specifically upregulates the motivational component of sexual behavior — the "wanting" dimension — rather than the consummatory response alone. This CNS-first mechanism may benefit people whose dysfunction is rooted in desire rather than physical performance, including those for whom vascular-targeting drugs have limited effect.
Because the mechanism is central rather than peripheral, it does not require sexual stimulation to initiate a response — a key functional distinction noted in clinical trial protocols.
2. Phase 3 Clinical Evidence in Female HSDD
The strongest evidence for PT-141 comes from the RECONNECT trials — two randomized, double-blind, placebo-controlled phase 3 studies in premenopausal women with acquired, generalized HSDD. The published RECONNECT data showed statistically significant improvements in satisfying sexual events (SSEs) and Female Sexual Function Index desire scores versus placebo.
In the pooled analysis, women using Vyleesi (bremelanotide 1.75 mg subcutaneous) reported approximately 0.5 more SSEs per month compared to placebo and meaningful reductions in distress related to low desire — the FDA-required co-primary endpoint.
These results supported the 2019 FDA approval of Vyleesi for HSDD in premenopausal women. Compounded bremelanotide (PT-141) is formulated by a compounding pharmacy and has not undergone FDA's own approval review.
3. Off-Label Research in Male Sexual Dysfunction
Early-phase studies explored PT-141 in men with erectile dysfunction, particularly those who did not respond to PDE5 inhibitors. A phase 2 study found that intranasal bremelanotide produced penile erections in a dose-dependent fashion, with effects emerging within 30–60 minutes of administration.
Men with psychogenic ED or low desire alongside adequate vascular function may represent a population where a centrally acting agent offers a complementary approach. These uses are off-label; intranasal bremelanotide was not advanced for FDA approval in men due to blood pressure findings observed with that route of administration.
Subcutaneous PT-141 — the form studied in the RECONNECT trials — carries a different pharmacokinetic profile and is the formulation relevant to current compounding practice.
4. Mechanistically Distinct from PDE5 Inhibitors
PDE5 inhibitors block phosphodiesterase-5 in vascular smooth muscle, increasing cyclic GMP and producing vasodilation — they require sexual stimulation and a functional nitric oxide pathway. PT-141 bypasses this pathway entirely, working upstream at the neuroendocrine level to influence desire before any peripheral vascular signal.
The two mechanisms are not mutually exclusive. Some research has examined whether combining melanocortin agonism with PDE5 inhibition might address both desire and performance components simultaneously. For a detailed comparison of PT-141 with other centrally acting peptides, see our analysis of PT-141 vs. kisspeptin.
This mechanistic distinction also means PT-141 does not share PDE5 inhibitors' contraindication with nitrates — though it carries its own side-effect profile, most notably transient nausea and temporary increases in blood pressure.
5. Potential Additive Effects When Combined with PDE5 Inhibitors
Because the two mechanisms are upstream and downstream of each other, early research asked whether combining them could produce additive benefit. A pilot study found that men who were partial or non-responders to sildenafil showed improved outcomes when bremelanotide was co-administered, suggesting additive rather than redundant effects.
This remains an emerging and incompletely characterized area. Combination use would require careful clinical oversight — particularly monitoring for blood pressure changes — and is not a standard protocol. The mechanistic rationale (CNS desire activation plus peripheral vascular optimization) is scientifically coherent and has prompted ongoing investigation.
At TelosRX, licensed providers review each case asynchronously and design protocols based on individual health history, prior treatments, and goals. Compounded PT-141 is not FDA-approved, and approval is not guaranteed.
Dosing and Administration Overview
In the RECONNECT trials, Vyleesi was dosed at 1.75 mg subcutaneous injection administered approximately 45 minutes before anticipated sexual activity. The prescribing information recommends no more than one dose per 24 hours and no more than eight doses per month based on the trial population studied.
Compounded PT-141 protocols may vary. A licensed provider will determine whether PT-141 is appropriate, the indicated dose, and how it integrates with any other health conditions or medications. This is not a self-prescribed peptide.
Who the Research Studied
The RECONNECT trials enrolled premenopausal women with acquired, generalized HSDD — meaning desire was previously present, then declined, and the decline was not situational. Phase 2 male ED studies enrolled men with organic or psychogenic ED without contraindications to experimental agents.
Individuals with uncontrolled hypertension, cardiovascular disease, or certain medication interactions were excluded from trials. A complete health history is needed before any consideration of PT-141. For broader context on peptide-based approaches to libido, see our review of peptides for libido including PT-141 and kisspeptin.
Frequently Asked Questions
Is PT-141 the same as Vyleesi?
PT-141 is the research name for bremelanotide, the same active molecule. Vyleesi is the FDA-approved branded version indicated for female HSDD. Compounded PT-141 is not FDA-approved and is prepared under federal compounding regulations.
How quickly does PT-141 take effect?
In the RECONNECT trials, Vyleesi was administered approximately 45 minutes before anticipated sexual activity. Some participants noted effects within 30 minutes; individual onset varies depending on dose, metabolism, and other factors.
Can men use PT-141?
PT-141 is FDA-approved only for premenopausal women with HSDD. Use in men is off-label. Phase 2 studies showed dose-dependent effects in men with ED, but the intranasal route was not advanced for male approval due to blood pressure findings.
What are the most common side effects?
In clinical trials, the most frequently reported side effects were nausea (approximately 40% of participants), flushing, and transient increases in blood pressure. Nausea typically resolved within 12 hours of administration.
Is compounded PT-141 legal?
Compounded medications can be legally prepared by licensed compounding pharmacies under federal compounding regulations. They are not FDA-approved. A prescription and licensed provider oversight are required.
Does PT-141 require sexual stimulation to work?
Unlike PDE5 inhibitors, PT-141's CNS mechanism does not strictly require sexual stimulation to initiate a response — it acts at the desire and motivational level. Individual responses vary significantly, and clinical context matters.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.